INDOCO Q2 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Indoco Remedies reported Q2 FY27 consolidated revenue of Rs. 5,069 million, up 7.4% YoY, crossing the Rs. 500 crore milestone for the first time. Growth was driven by international formulations (+12.1%), particularly regulated markets (+21.1%), while domestic formulations declined 5.9% due to weak acute therapies. EBITDA margin was 9.2% (flat YoY, down QoQ), impacted by higher material costs and Rs. 13 crore freight cost increase. Management maintained domestic high single-digit growth guidance and expects decent double-digit international growth. Key headwinds include USFDA observations at Goa plant (decision by December), ophthal portfolio divestment impact (Rs. 10-12 crore), and geopolitical cost pressures. Management remains optimistic on long-term growth, with infrastructure capable of 4X current international topline.
Management Tone
- Prepared Remarks: Good — Management expressed pride in crossing Rs. 500 crore quarterly revenue, highlighted strong international growth (regulated markets +21.1%, Europe +23.5%, US +16.4%) and new product traction, while acknowledging margin pressure from external cost pressures but remaining optimistic on long-term growth
- Q&A Session: Neutral — Analysts pressed on domestic growth miss, expense control, and USFDA audit timeline; management acknowledge near-term challenges including acute portfolio decline, freight cost headwinds, and a Rs. 10-12 crore negative impact from ophthal portfolio divestment, while maintaining hope for H2 recovery
Revenue Growth Drivers
- Domestic acute therapy weakness (Febrex Plus and Oxipod/ATL degrew ~20% due to absent monsoon and seasonal headwinds)
- Ophthal portfolio divestment in Africa impacting emerging markets revenue by Rs. 10-12 crore annually
- Strong regulated market growth driven by Europe (+23.5%) and US (+16.4%) from new product launches and better supply
Growth vs Margin Focus
Management emphasized both growth and margins. They highlighted strong revenue growth (crossing Rs. 500 crore) while also focusing on operational efficiencies, cost management, and improving profitability. They are investing in R&D and new products for future growth while controlling costs (R&D capp
About Indoco Remedies Limited
Indoco Remedies Limited (INDOCO) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.